ENERGYA/TALENTIA ICDs & CRT-Ds, SmartTouch Programmer Software Modules, SmartView Connect App, & RMS
MicroPort CRM S.r.l. · Decision date Nov 25, 2025
What did the FDA approve?
FDA records P060027/S106 as a supplement to PMA P060027, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 25, 2025.
FDA approval order statement
approval for the ENERGYA/TALENTIA family of ICDs and CRT-Ds and associated SmartTouch Programmer software modules, and updates to the Remote Monitoring System.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 25, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P060027/S106
- Regulatory pathway
- PMA supplement
- Applicant
- MicroPort CRM S.r.l.
- Product code
- NIK
- Decision code
- APPR
- Decision date
- Nov 25, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D).
- Applicant
- MicroPort CRM S.r.l.
- Product code
- NIK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P060027/S106 received
Application receipt date recorded by FDA.
P060027/S107 · Related supplement
Platinium CRT-D 1711; Platinium CRT-D 1741; Platinium 4LV CRT-D 1744; ENERGYA CRT-D 3711; ENERGYA CRT-D 3741; ENERGYA 4L
P060027/S106 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P060027. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P060027
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| MicroPort CRM S.r.l. | PMA supplement | Jul 23, 2025 | FDA |
Explore the linked device profile
Other records with product code NIK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Sep 25, 2026 | FDA | |
Tachy Pulse GeneratorsP010012/S612 | Boston Scientific Corp | PMA supplement | Aug 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
MicroPort CRM S.r.l.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Via Crescentino S.N., Saluggia, 13040
Sources and methodology
- Original FDA record: P060027/S106
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



